iPSK3
MUSCSDi001-A
General
Donor Information
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA7023731 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | No |
| Was the consent voluntarily given? | No |
| Has the donor been informed that participation will not directly influence their personal treatment? | No |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Please provide contact information of the holder of the original Donor Information Sheet. | De-identified fibroblasts were procured by ATCC in 1994 from a donor. No donor information is available. Please see attached letter from ATCC for further details. |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | No |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | MUSC Stem Cell Research Oversight Committee |
| Approval number | MUSC SCRO #8 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell line name | ATCC cell line CRL2097 |
| Source cell type | |
| Source cell origin | |
| Source cell line vendor | ATCC |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex | |||||||||||||||
| Feeder cells |
MEF |
|||||||||||||||
| Passage method |
Enzymatically
Accutase
|
|||||||||||||||
| O2 Concentration | 4 % | |||||||||||||||
| CO2 Concentration | 5 % | |||||||||||||||
| Medium |
Other medium:
Base medium: DMEM/Ham's F-12
Main protein source: Serum concentration: % Supplements
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| SSEA-4 |
Yes |
|
|
|||
| TRA 1-60 |
Yes |
|
||||
| CD13 |
No |
|
Differentiation Potency
In vitro directed differentiation
| Marker | Expressed |
| HNF4A |
Yes |
| AFP |
Yes |
| Albumin |
Yes |
| FoxA2 |
Yes |
| E-Cadherin |
Yes |
In vitro directed differentiation
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XY (Normal)
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.